Abstract PS10-58: Cost effectiveness of routine cardiac imaging during adjuvant trastuzumab in HER2-positive breast cancer

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-018-0634-5 ◽

2018 ◽

Vol 36 (4) ◽

pp. 505-505

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

Value in Health ◽

10.1016/j.jval.2011.02.916 ◽

2011 ◽

Vol 14 (3) ◽

pp. A165

Author(s):

T.T.T. Nguyen ◽

R. Yagudina ◽

A.U. Kulikov

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

Value in Health ◽

10.1016/j.jval.2014.08.107 ◽

2014 ◽

Vol 17 (7) ◽

pp. A735 ◽

Cited By ~ 1

Author(s):

Nguyen TTC ◽

Nguyen TTT

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Stage ◽

Cost Effectiveness Analysis ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Effectiveness Analysis ◽

Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

PharmacoEconomics ◽

10.1007/s40273-018-0620-y ◽

2018 ◽

Vol 36 (3) ◽

pp. 381-382

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-017-0557-6 ◽

2017 ◽

Vol 36 (1) ◽

pp. 91-103 ◽

Cited By ~ 11

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Randomised Controlled ◽

Adjuvant Trastuzumab in HER2-Positive Breast Cancer: Observational Monocentric Study of 84 Cases

Annals of Oncology ◽

10.1093/annonc/mdt079.3 ◽

2013 ◽

Vol 24 ◽

pp. iii16

Author(s):

M. Aitelhaj ◽

S. Lkhoyaali ◽

G. Rais ◽

A. Mohtaram ◽

S. Boutayeb ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Medical Molecular Morphology ◽

10.1007/s00795-018-0208-9 ◽

2018 ◽

Vol 52 (2) ◽

pp. 106-113

Author(s):

Naoki Kanomata ◽

Junichi Kurebayashi ◽

Takuya Moriya

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer

Korean Journal of Clinical Oncology ◽

10.14216/kjco.18019 ◽

2018 ◽

Vol 14 (2) ◽

pp. 108-115

Author(s):

Ashraf Mahmoud El-Enbaby ◽

Nadia Ahmed Abd El Moneim ◽

Gehan Abd El atti Khedr ◽

Yasmine Mohamed Nagy Elwany

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.347 ◽

2020 ◽

Vol 31 ◽

pp. S331

Author(s):

C. Molinelli ◽

L. Del Mastro ◽

S. Giraudi ◽

A. Ballestrero ◽

F. Carli ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Cardiac Safety ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽